Terapie SARS-Cov-2 | Inibitori interleuchina-6 (Tocilizumab/Sarilumab)
In rosso le review, in verde gli RCT.
- The Lancet, 1 maggio 2021 | “Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial”
- New England Journal of Medicine, 22 aprile 2021 | “Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19”
- Science, 11 febbraio 2021 | “World’s largest COVID-19 drug trial identifies second compound that cuts risk of death”
- BMJ, 20 gennaio 2021 | “Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial”